$PDEX
PRO DEX INC Stock $pdex

$pdex Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000107997323001522 Filed on November 02, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$12.59M	$11.94M
YoY Change	11.58%	7.68%
Cost Of Revenue	$9.786M	$8.280M
YoY Change	13.02%	1.83%
Gross Profit	$2.802M	$3.658M
YoY Change	6.82%	23.75%
Gross Profit Margin	22.26%	30.64%
Selling, General & Admin	$1.237M	$1.020M
YoY Change	21.39%	-5.29%
% of Gross Profit	44.15%	27.88%
Research & Development	$788.0K	$805.0K
YoY Change	68.74%	-13.35%
% of Gross Profit	28.12%	22.01%
Depreciation & Amortization	$288.0K	$282.0K
YoY Change	50.79%	46.11%
% of Gross Profit	10.28%	7.71%
Operating Expenses	$2.025M	$1.825M
YoY Change	36.27%	-9.02%
Operating Profit	$777.0K	$1.833M
YoY Change	-31.66%	92.95%
Interest Expense	$139.0K	$133.0K
YoY Change	8.59%	2.31%
% of Operating Profit	17.89%	7.26%
Other Income/Expense, Net		-$2.662M
YoY Change		-873.84%
Pretax Income	$620.0K	-$829.0K
YoY Change	-47.19%	-164.06%
Income Tax	$120.0K	-$214.0K
% Of Pretax Income	19.35%
Net Earnings	$500.0K	-$615.0K
YoY Change	-43.12%	-157.16%
Net Earnings / Revenue	3.97%	-5.15%
Basic Earnings Per Share	$0.14	-$0.17
Diluted Earnings Per Share	$0.14	-$0.17
COMMON SHARES
Basic Shares Outstanding	3.547M shares	3.547M shares
Diluted Shares Outstanding	3.612M shares	3.547M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.601M	$8.006M
YoY Change	165.3%	45.56%
Cash & Equivalents	$1.289M	$1.904M
Short-Term Investments	$7.312M	$6.102M
Other Short-Term Assets	$1.313M	$790.0K
YoY Change	-21.09%	-47.85%
Inventory	$15.03M	$16.26M
Prepaid Expenses
Receivables	$13.17M	$11.03M
Other Receivables	$0.00	$420.0K
Total Short-Term Assets	$36.60M	$31.42M
YoY Change	16.61%	-1.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.331M	$4.952M
YoY Change	2.46%	2.06%
Goodwill
YoY Change
Intangibles	$68.00K	$75.00K
YoY Change	-30.61%	-30.56%
Long-Term Investments	$1.509M	$5.090M
YoY Change	-12.57%	169.45%
Other Assets	$42.00K	$42.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$14.83M	$18.16M
YoY Change	-8.43%	12.59%
TOTAL ASSETS
Total Short-Term Assets	$36.60M	$31.42M
Total Long-Term Assets	$14.83M	$18.16M
Total Assets	$51.43M	$49.59M
YoY Change	8.09%	3.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.909M	$2.740M
YoY Change	-13.53%	-22.8%
Accrued Expenses	$2.846M	$2.701M
YoY Change	-14.12%	-16.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.846M	$2.840M
YoY Change	23.67%	-13.86%
Total Short-Term Liabilities	$9.990M	$8.281M
YoY Change	-14.36%	-29.06%
LONG-TERM LIABILITIES
Long-Term Debt	$8.228M	$8.570M
YoY Change	-14.2%	-13.63%
Other Long-Term Liabilities	$1.415M	$1.530M
YoY Change	-23.51%	-21.7%
Total Long-Term Liabilities	$9.651M	$10.11M
YoY Change	-15.64%	-14.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.990M	$8.281M
Total Long-Term Liabilities	$9.651M	$10.11M
Total Liabilities	$19.64M	$18.39M
YoY Change	-14.99%	-21.91%
SHAREHOLDERS EQUITY
Retained Earnings	$24.71M	$24.21M
YoY Change	37.72%	41.88%
Common Stock	$7.078M	$6.987M
YoY Change	8.34%	-4.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.79M	$31.20M
YoY Change
Total Liabilities & Shareholders Equity	$51.43M	$49.59M
YoY Change	8.09%	3.38%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$500.0K	-$615.0K
YoY Change	-43.12%	-157.16%
Depreciation, Depletion And Amortization	$288.0K	$282.0K
YoY Change	50.79%	46.11%
Cash From Operating Activities	$712.0K	$392.0K
YoY Change	-280.25%	-86.45%
INVESTING ACTIVITIES
Capital Expenditures	$629.0K	$126.0K
YoY Change	23.58%	-29.21%
Acquisitions
YoY Change
Other Investing Activities	-$1.250M	$0.00
YoY Change	-125100.0%	-100.0%
Cash From Investing Activities	-$1.879M	-$126.0K
YoY Change	269.88%	40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	560.0K	-$1.298M
YoY Change	-137.01%	52.17%
NET CHANGE
Cash From Operating Activities	712.0K	$392.0K
Cash From Investing Activities	-1.879M	-$126.0K
Cash From Financing Activities	560.0K	-$1.298M
Net Change In Cash	-607.0K	-$1.032M
YoY Change	-74.88%	-152.95%
FREE CASH FLOW
Cash From Operating Activities	$712.0K	$392.0K
Capital Expenditures	$629.0K	$126.0K
Free Cash Flow	$83.00K	$266.0K
YoY Change	-109.18%	-90.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments		usd
CY2023Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000788920
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable		usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2023Q3	pdex	Realized Gain On Sale Of Marketable Equity Investments RealizedGainOnSaleOfMarketableEquityInvestments		usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity		usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023Q3	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2023Q3	pdex	Payment Of Employee Payroll Taxes On Net Issuance Of Common Stock PaymentOfEmployeePayrollTaxesOnNetIssuanceOfCommonStock		usd
CY2023Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	0-14942
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	PRO-DEX, INC.
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1261240
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	2361 McGaw Avenue
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2023Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
CY2023Q3	dei	City Area Code CityAreaCode	(949)
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	769-3200
CY2023Q3	dei	Security12b Title Security12bTitle	Common Stock, no par value
CY2023Q3	dei	Trading Symbol TradingSymbol	PDEX
CY2023Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3547330	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1904000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2936000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	1010000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	1134000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11034000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9952000	usd
CY2023Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	591000	usd
CY2023Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	494000	usd
CY2023Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	420000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	16264000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	16167000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	201000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	296000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	31424000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	30979000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6226000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6249000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4952000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5079000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1774000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1872000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	75000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	81000	usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	5092000	usd
CY2023Q2	us-gaap	Long Term Investments LongTermInvestments	7521000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2023Q3	us-gaap	Assets Assets	49585000	usd
CY2023Q2	us-gaap	Assets Assets	51823000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2740000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2261000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2701000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3135000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	453000	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2840000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	3827000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8281000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9676000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1529000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1638000	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	8572000	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	8911000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10109000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10557000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	18390000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	20233000	usd
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3547330	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3547330	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3545309	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3545309	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	6987000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6767000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	24208000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	24823000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	31195000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31590000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49585000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51823000	usd
CY2023Q3	us-gaap	Revenues Revenues	11938000	usd
CY2022Q3	us-gaap	Revenues Revenues	11087000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	8280000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	8131000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	3658000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	2956000	usd
CY2023Q3	us-gaap	Selling Expense SellingExpense	25000	usd
CY2022Q3	us-gaap	Selling Expense SellingExpense	53000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	995000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1024000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	805000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	929000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1825000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2006000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1833000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	950000	usd
CY2023Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	24000	usd
CY2022Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	218000	usd
CY2022Q3	pdex	Realized Gain On Sale Of Marketable Equity Investments RealizedGainOnSaleOfMarketableEquityInvestments	6000	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2553000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	425000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	133000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	130000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2662000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	519000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-829000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1469000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-214000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	266000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-615000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1203000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3546737	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3616392	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3546737	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3694959	shares
CY2023Q3	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	3547330	shares
CY2022Q3	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	3606422	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	31590000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-615000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1203000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	31195000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	26306000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-615000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1203000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	282000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	193000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	189000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	207000	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2553000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	425000	usd
CY2023Q3	pdex	Noncash Lease Expense Recovery NoncashLeaseExpenseRecovery	-2000	usd
CY2022Q3	pdex	Noncash Lease Expense Recovery NoncashLeaseExpenseRecovery	2000	usd
CY2023Q3	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	-4000	usd
CY2022Q3	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	-2000	usd
CY2022Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	6000	usd
CY2022Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	80000	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1082000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-4337000	usd
CY2023Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	97000	usd
CY2022Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-123000	usd
CY2023Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	97000	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2986000	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-95000	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	138000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	35000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	273000	usd
CY2022Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-162000	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-873000	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	187000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	392000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2892000	usd
CY2023Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	178000	usd
CY2022Q3	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	88000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-126000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90000	usd
CY2023Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1330000	usd
CY2022Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1318000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1000000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	32000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	42000	usd
CY2022Q3	pdex	Payment Of Employee Payroll Taxes On Net Issuance Of Common Stock PaymentOfEmployeePayrollTaxesOnNetIssuanceOfCommonStock	-223000	usd
CY2022Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	354000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1298000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-853000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1032000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1949000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2936000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	849000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1904000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2798000	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	140000	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	89000	usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	660000	usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	241000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	425000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	519000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1469000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	266000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1203000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2023Q3	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_ztMNTxnDeys" style="font: bold 10pt Times New Roman, Times, Serif; margin: 8.1pt 0 10pt">NOTE 2. <span id="xdx_820_zwbRa5N38JR3">DESCRIPTION OF BUSINESS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23pt">We specialize in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23pt"><span style="letter-spacing: 0pt">In August 2020, we formed a wholly owned subsidiary, PDEX Franklin, LLC (“PDEX Franklin”), to hold title for an approximate 25,000 square foot industrial building in Tustin, California (the “Franklin Property”) that we acquired on November 6, 2020, in order to allow for the continued growth of our business. The condensed consolidated financial statements include the accounts of the Company and PDEX Franklin and all significant inter-company accounts and transactions have been eliminated. This subsidiary has no separate operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23pt"><span style="letter-spacing: 0pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
CY2023Q3	pdex	Overtime Revenue Recognition OvertimeRevenueRecognition	190000	usd
CY2022Q3	pdex	Overtime Revenue Recognition OvertimeRevenueRecognition	907000	usd
CY2023Q3	pdex	Pointintime Revenue Recognition PointintimeRevenueRecognition	11748000	usd
CY2022Q3	pdex	Pointintime Revenue Recognition PointintimeRevenueRecognition	10180000	usd
CY2023Q3	us-gaap	Revenues Revenues	11938000	usd
CY2022Q3	us-gaap	Revenues Revenues	11087000	usd
CY2023Q3	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	usd
CY2022Q3	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	551000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	494000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	710000	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	219000	usd
CY2022Q3	us-gaap	Accretion Expense AccretionExpense	333000	usd
CY2023Q3	pdex	Amounts Reclassified To Cost Of Sales AmountsReclassifiedToCostOfSales	105000	usd
CY2022Q3	pdex	Amounts Reclassified To Cost Of Sales AmountsReclassifiedToCostOfSales	448000	usd
CY2023Q3	pdex	Amounts Allocated To Discounts For Standalone Selling Price AmountsAllocatedToDiscountsForStandaloneSellingPrice	17000	usd
CY2022Q3	pdex	Amounts Allocated To Discounts For Standalone Selling Price AmountsAllocatedToDiscountsForStandaloneSellingPrice	8000	usd
CY2023Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	591000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	587000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1013000	usd
CY2023Q3	us-gaap	Proceeds From Customers For Progress Payments ProceedsFromCustomersForProgressPayments	43000	usd
CY2022Q3	us-gaap	Proceeds From Customers For Progress Payments ProceedsFromCustomersForProgressPayments	389000	usd
CY2023Q3	pdex	Amounts Reclassified To Revenue AmountsReclassifiedToRevenue	43000	usd
CY2022Q3	pdex	Amounts Reclassified To Revenue AmountsReclassifiedToRevenue	551000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	851000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	1010000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	1134000	usd
CY2023Q3	pdex	Marketable Securities Warrant Non Current MarketableSecuritiesWarrantNonCurrent	3670000	usd
CY2023Q2	pdex	Marketable Securities Warrant Non Current MarketableSecuritiesWarrantNonCurrent	6160000	usd
CY2023Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1422000	usd
CY2023Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1361000	usd
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities	6102000	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	8655000	usd
CY2023Q3	pdex	Available For Sale Securities Amortized Costs AvailableForSaleSecuritiesAmortizedCosts	2714000	usd
CY2023Q2	pdex	Available For Sale Securities Amortized Costs AvailableForSaleSecuritiesAmortizedCosts	2714000	usd
CY2023Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	200000	usd
CY2023Q3	pdex	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	362000	usd
CY2023Q3	pdex	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	162000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-219000	usd
CY2023	pdex	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	286000	usd
CY2023	pdex	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	67000	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1010000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1134000	usd
CY2023Q3	us-gaap	Share Price SharePrice	2.60
CY2023Q2	us-gaap	Share Price SharePrice	3.98
CY2023Q3	us-gaap	Option Indexed To Issuers Equity Strike Price1 OptionIndexedToIssuersEquityStrikePrice1	0.68
CY2023	us-gaap	Option Indexed To Issuers Equity Strike Price1 OptionIndexedToIssuersEquityStrikePrice1	0.69
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P2Y2M19D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P2Y5M23D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.600	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.600	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0503	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0468	pure
CY2022Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	54000	usd
CY2023Q3	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-2000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	14000	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	7964000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	8824000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	4516000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	3686000	usd
CY2023Q3	pdex	Inventory Sub Assemblies InventorySubAssemblies	2146000	usd
CY2023Q2	pdex	Inventory Sub Assemblies InventorySubAssemblies	2387000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1638000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1270000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	16264000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	16167000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	133000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	127000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	75000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	81000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	27000	usd
CY2023Q3	us-gaap	Product Warranty Expense ProductWarrantyExpense	189000	usd
CY2023	us-gaap	Product Warranty Expense ProductWarrantyExpense	200000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	200000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	340000	usd
CY2023Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	24000	usd
CY2023Q3	pdex	Product Warranty Accrual Amortization ProductWarrantyAccrualAmortization	33000	usd
CY2022Q3	pdex	Product Warranty Accrual Amortization ProductWarrantyAccrualAmortization	42000	usd
CY2023Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	189000	usd
CY2022Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	366000	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	64800	shares
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-615000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1203000	usd
CY2023Q3	pdex	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3547000	shares
CY2022Q3	pdex	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3616000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-615000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1203000	usd
CY2023Q3	pdex	Weightedaverage Shares Outstanding Diluted WeightedaverageSharesOutstandingDiluted	3547000	shares
CY2022Q3	pdex	Weightedaverage Shares Outstanding Diluted WeightedaverageSharesOutstandingDiluted	3616000	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	79000	shares
CY2023Q3	pdex	Weighted Average Shares Used In Calculation Of Diluted Earnings Per Share WeightedAverageSharesUsedInCalculationOfDilutedEarningsPerShare	3547000	shares
CY2022Q3	pdex	Weighted Average Shares Used In Calculation Of Diluted Earnings Per Share WeightedAverageSharesUsedInCalculationOfDilutedEarningsPerShare	3695000	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	48000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.26	pure
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.18	pure
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y8M26D
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	425000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0553	pure
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	127000	usd
CY2023Q3	us-gaap	Cost Maintenance CostMaintenance	12000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	392000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	535000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	551000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	567000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	143000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2188000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	233000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1955000	usd

Files In Submission

Name	View Source	Status
pdex-20230930_def.xml	Edgar Link	unprocessable
0001079973-23-001522-index-headers.html	Edgar Link	pending
0001079973-23-001522-index.html	Edgar Link	pending
0001079973-23-001522.txt	Edgar Link	pending
0001079973-23-001522-xbrl.zip	Edgar Link	pending
ex31z1.htm	Edgar Link	pending
ex31z2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pdex-20230930.xsd	Edgar Link	pending
pdex_10q-093023.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pdex-20230930_cal.xml	Edgar Link	unprocessable
pdex-20230930_lab.xml	Edgar Link	unprocessable
pdex-20230930_pre.xml	Edgar Link	unprocessable
pdex_10q-093023_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PDEX
PRO DEX INC Stock $pdex

2023 Q4 Form 10-Q Financial Statement

#000107997323001522 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PDEX PRO DEX INC Stock $pdex

2023 Q4 Form 10-Q Financial Statement

#000107997323001522 Filed on November 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PDEX
PRO DEX INC Stock $pdex